The Effect of Manufacturing Methods and Different Shapes on the Release Pattern of Diclofenac Sodium Matrix Tablet
DOI:
https://doi.org/10.3329/sjps.v2i2.5828Keywords:
Matrix tablet, release pattern, direct compression, wet granulation, PEG 600, Kollidon SRAbstract
In the present study sustained release diclofenac sodium matrix tablets were prepared using Kollidon SRpolymer. Hydroxypropyl methylcellulose (HPMC 15 cps) and poly ethylene glycol (PEG-600) polymers
respectively were used in formulating tablets prepared by direct compression and wet granulation methods.
The polymers were used to explore the release pattern of the drug into the dissolution media. The tablets
were also prepared in various shapes (caplet oval, round oval and flat oval). A comparatively higher release
rate of drug was obtained from the polymer HPMC 15 cps at 10% concentration for directly compressed
matrix tablet than those containing 20% of HPMC after a definite period of time. In wet granulation process,
10% PEG-600 containing tablets showed a better release than those containing 20% PEG. The drug release
was also found to be sustained in case of wet granulation method than that of the direct compression method.
Again the caplet shaped tablets in case of direct compression method showed better release rate of drug than
those of the round oval and flat oval shaped tablets. Thus the result of this study shows that the proper
selection of the percentage of polymer and the suitable shape of tablet and proper manufacturing method can
provide a greater opportunity in designing sustained release dosage forms.
Key words: Matrix tablet; release pattern; direct compression; wet granulation; PEG 600; Kollidon SR.
DOI: 10.3329/sjps.v2i2.5828
Stamford Journal of Pharmaceutical Sciences Vol.2(2) 2009: 76-80
Downloads
949
4934
Downloads
How to Cite
Issue
Section
License
As a condition of publication, all authors must transfer copyright to the Department of Pharmacy. Manuscripts submitted under multiple authorship are reviewed on the assumption that all listed authors concur in the submission, and that the final version of the manuscript has been seen and approved by them.Each author must agree to this statement
Authorship: This manuscript is the original work of the authors, each of whom has read and approved of the work. Each author satisfied the requirements contained in 'Author Guidelines' having participated sufficiently in the work to take public responsibility for the content. This participation includes:
- Conception or design of the study, or analysis and interpretation of data, or both
- Drafting the article or revising it for critically important intellectual content
- Approval of the final 'to be published' version
All authors must take responsibility for the integrity of the work. Participating solely in the collection of data does not justify authorship.
Prior publication: This work is not currently under consideration by any other journal. Information about prior publication of any part of this work, or inclusion of patients detailed herein in any other work, has been provided in the cover letter.
Conflict of interest: Details of any financial or other relationship between any author and any other party that may lead to a conflict of interest with the subject or any materials mentioned in this article have been disclosed in the cover letter.
